Key terms
About GNFT
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GNFT news
Apr 15
9:02pm ET
GENFIT Announces Upcoming Shareholders Meeting
Apr 08
3:25am ET
Buy Rating Reiterated for Genfit SA Amidst Promising Clinical Developments and Strong Financial Outlook
Apr 06
9:45pm ET
Kepler Capital Keeps Their Buy Rating on Genfit (GNFTF)
Apr 05
2:27pm ET
GENFIT Releases Key Financial Documents for 2023
Apr 05
8:20am ET
Analysts Offer Insights on Healthcare Companies: Genfit SA (GNFT) and Laboratory (LH)
Apr 04
5:57pm ET
GENFIT Announces Strong 2023 Financials and Progress
Mar 26
9:45pm ET
Kepler Capital Keeps Their Buy Rating on Genfit (GNFTF)
Feb 13
8:35pm ET
Genfit (GNFTF) Gets a Buy from Kepler Capital
No recent press releases are available for GNFT
GNFT Financials
Key terms
Ad Feedback
GNFT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GNFT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
